

Xofluza - (40, 80mg ; Tablet)

Generic Name	Baloxavir Marboxil	Innovator	Genentech, Inc.
Dosage	40, 80mg ; Tablet	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	XOFLUZATM is a polymerase acidic (PA) endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Xofluza - (2MG/ML,30MG/PACKET,40MG/PACKET ; For Suspension)

Generic Name	Baloxavir Marboxil	Innovator	Genentech, Inc.
Dosage	2MG/ML,30MG/PACKET,40MG/PACKET ; For Suspension	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for: • Treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours and who are: -otherwise healthy adults and pediatric patients 5 years of age and older, OR -adults and pediatric patients 12 years of age and older who are at high- risk of developing influenza-related complications. • Post-exposure prophylaxis of influenza in patients 5 years of age and older following contact with an individual who has influenza.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.